Vaxart, Inc. (VXRT) Stock Price & Analysis
Vaxart, Inc. (VXRT) fell 3.12% to USD 0.58 as of June 10, 2026 at 00:52 UTC, according to Nexqual real-time market data.
VXRT last closed at USD 0.6; the session ranged USD 0.57–0.62 on volume of 188,215 shares. Market capitalization is $140.39M, with a 52-week range of USD 0.26–0.84 (OQX). Source: Nexqual, June 10, 2026 at 00:52 UTC.
Key Statistics (as of June 10, 2026 at 00:52 UTC)
| Price | USD 0.58 |
|---|---|
| Change | ▼ 3.12% (down) |
| Previous Close | USD 0.6 |
| Open | USD 0.6 |
| Day Range | USD 0.57 – 0.62 |
| 52-Week Range | USD 0.26 – 0.84 |
| Volume | 188,215 shares |
| Market Cap | $140.39M |
| Exchange | OQX |
Technical Analysis (VXRT)
Nexqual's technical model rates VXRT "SELL" based on 2 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 00:52 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 35.64 (neutral) |
| vs SMA50 | Below (USD 0.68) |
| MACD | -0.03 (negative) |
Analyst Ratings (VXRT)
Wall Street analysts rate VXRT "Strong Buy" based on 2 analysts, with a mean price target of USD 3 (range USD 2–4), per Nexqual as of June 10, 2026 at 00:52 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 2 |
| Mean Target | USD 3 |
| High Target | USD 4 |
| Low Target | USD 2 |
| Buy / Hold / Sell | 3 / 0 / 0 |
Earnings (VXRT)
| Next Earnings Date | 2026-05-07 |
|---|---|
| EPS Estimate | USD -0.21 |
| Revenue Estimate | $50.50M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0.02 vs est 0.02 ▲ beat |
| 2025-12-31 | USD 0.24 vs est -0.08 ▲ beat |
| 2025-09-30 | USD -0.04 vs est -0.07 ▲ beat |
| 2025-06-30 | USD -0.07 vs est -0.1 ▲ beat |
Source: Nexqual, June 10, 2026 at 00:52 UTC.
Financials & Fundamentals (VXRT)
| Total Revenue | $255.61M |
|---|---|
| Revenue Growth (YoY) | +87.90% |
| Gross Margin | +21.66% |
| Operating Margin | +13.19% |
| Profit Margin | +14.51% |
| ROE | +53.10% |
| Debt / Equity | 12.97 |
| Current Ratio | 1.71 |
| Total Cash | $61.02M |
| Total Debt | $12.20M |
| Free Cash Flow | $-32.71M |
Source: Nexqual, June 10, 2026 at 00:52 UTC.
Financial Health Score (VXRT)
Nexqual rates Vaxart, Inc.'s overall financial health "Solid" across five dimensions, as of June 10, 2026 at 00:52 UTC.
| Growth | Strong — Revenue +727% YoY (annual) |
|---|---|
| Profitability | Mixed — Gross margin 22%, operating 13% |
| Balance Sheet | Strong — $61M cash vs $12M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$33M, burning cash |
| Efficiency | Strong — ROE 53%, ROA 14.1% |
Ownership (VXRT)
| Insider Ownership | +1.33% |
|---|---|
| Institutional Ownership | +0.05% |
| Shares Outstanding | 242.04M |
| Float | 238.37M |
| Short % of Float | +9.40% |
Source: Nexqual, June 10, 2026 at 00:52 UTC.
Leadership (VXRT)
Vaxart, Inc. is led by Steven Lo (age 58), President, CEO & Director, per Nexqual as of June 10, 2026 at 00:52 UTC.
| President, CEO & Director | Steven Lo (age 58) |
|---|---|
| Senior VP & Chief Scientific Officer | Sean N. Tucker (age 57) |
| CFO, Principal Accounting Officer & Principal Financial Officer | Jeroen Grasman (age 55) |
| Senior Vice President of Human Resources | Laurie Hastings |
| Senior Vice President of Quality | Rajesh Kapoor |
From Vaxart, Inc.'s Latest SEC 10-K Filing (filed 2026-03-13)
Key Strengths & Strategy (as disclosed to the SEC)
- Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform.
- The company also provides VAAST (Vector-Adjuvant-Antigen Standardized Technology) Platform, a unique modular vaccine platform.
- It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| INO | Inovio Pharmaceuticals, Inc. | USD 1.1 | ▲ 2.8% |
| SRNE | Sorrento Therapeutics, Inc. | USD 0 | ▲ 0% |
| IBIO | iBio, Inc. | USD 1.7 | ▼ 6.59% |
| CODX | Co-Diagnostics, Inc. | USD 4.5 | ▼ 20.07% |
| NVAX | Novavax, Inc. | USD 8.67 | ▼ 8.64% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 00:52 UTC. This page is informational and not investment advice.